Allurion Technologies Inc

What they do

Allurion develops and markets the swallowable, Procedureless intragastric balloon for weight loss, along with associated digital health tools. The company sells its products primarily in Europe, the Middle East, and the Asia-Pacific region, with growing exposure in Latin America, Canada, and Africa. Revenue is generated from device sales and related services to healthcare providers and patients.

Revenue drivers

• Swallowable intragastric balloon — Core product offering; generates the majority of revenue from sales to healthcare providers and clinics. Revenue declined from $64.2M in 2022 to $15.2M in 2025.
• Digital health platform — Complementary software/app that supports patient monitoring and engagement; bundled with the balloon but may also be sold separately. Specific revenue split not disclosed.
• International markets — Geographic revenue diversification with primary exposure in Europe, Middle East, and Asia-Pacific; these regions drive most sales, with emerging opportunities in Latin America, Canada, and Africa.

Recent performance

For fiscal year 2025, Allurion reported revenue of $15.2 million, down from $32.1 million in 2024, and a net loss of $28.8 million. Quarterly revenue has been volatile: $3.4M (Q2 2025), $2.7M (Q3 2025), $3.6M (Q4 2025), and $2.9M (Q1 2026). Operating cash flow was negative $28.9 million in 2025. As of March 31, 2026, cash and equivalents totaled $5.1 million, with total liabilities of $91.9 million and negative shareholder equity of $77.9 million.

Strategy

Management has implemented a strategic restructuring plan including a reduction in force to cut costs and preserve cash. The company is focused on commercializing its intragastric balloon and expanding into new geographic markets. It is also working to maintain or relist its securities on a national exchange after receiving delisting notices. No new product launches or major investments were explicitly detailed in the provided filings.

Risks

• Going concern / liquidity — With only $5.1 million cash and ongoing operating losses, the company may not have sufficient funding to continue operations without additional financing.
• Delisting risk — Received delisting notices in March 2026, and there is no assurance it can maintain or relist on NYSE, NYSE American, or Nasdaq.
• Litigation and legal risks — The company faces potential litigation and disputes that could adversely impact its financial condition and operations.
• Foreign exchange exposure — A 10% adverse change in foreign exchange rates could have a material impact on revenue and expenses, given significant international operations.

Outlook

Management did not provide explicit forward guidance in the excerpts. They plan to focus on restructuring, cost reduction, and preserving cash while seeking additional funding. The company continues to monitor international market expansion and foreign exchange risks. Delisting and relisting efforts remain a priority.